An interventional study of Exercise in Medulloblastoma, Childhood, sponsored by Aron Onerup. Recruiting at 2 sites in 2 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Aron Onerup · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Medulloblastoma with a site in Germany — 3 open to participants now, 5 under way, 1 of them phase 3. Medulloblastoma · Germany.
Among the 15 studies in Medulloblastoma with a site in Germany, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is the only one with no phase, and was the 15th registered.
317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.
Browse Medulloblastoma studies →3 of the 15 studies in Medulloblastoma with a site in Germany are open now. Recruiting first, the newest first:
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Christian Dorfer · Sites in Germany, Austria, Netherlands
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 2
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 31 across 255 interventional studies indexed under Medulloblastoma.
Median enrollment 33 across the 11 interventional studies, 227 across the 4 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Aron Onerup as lead sponsor.
Aron Onerup has 1 study filed under Medulloblastoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Medulloblastoma with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02066220Phase 3Universitätsklinikum Hamburg-EppendorfInternational Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | 2026-12 |
| NCT06898684Aron OnerupMedulloblastoma Online Video-based Exercise Pilot Study | 2026-12 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Medulloblastoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma. The exercise sessions will be individualized and offered three times weekly during 12 weeks.
Tumors of the central nervous system (CNS) represent 25-30% of all cases of pediatric cancer in Sweden. The survival for children with a brain tumor has improved over the last years. The 5-year overall survival rate is now 70%, resulting in a growing number or survivors every year. Malignant brain tumors typically have a poor prognosis, and curative treatment usually requires a combination of neurosurgery, chemotherapy and/or radiotherapy. For the survivors, the cure often comes at the cost of long-term side effects. Finding effective ways to mitigate the long-term side effects after childhood brain tumor is important, since they can severely impact the survivors´ daily life.
There is growing evidence that physical exercise is beneficial to cognition and improves cardiorespiratory fitness and motor function. It appears to be important that interventions start early, within 1-2 years after radiotherapy. For this to be feasible in international multicenter trials, the intervention and outcome assessments will need to be delivered remotely. Whether this is feasible in children treated for medulloblastoma is not known.
The investigators will perform a pilot study to provide pivotal information on whether exercise training can be remotely delivered in the home environment in children treated for medulloblastoma. This will take exercise training from an interesting research concept into a scalable intervention that can be offered regardless of geographic location of the patient. The study will further define the validity and feasibility of in-home outcome assessments of cardiorespiratory, muscular fitness and motor function in children treated for medulloblastoma. If shown feasible, this will work as a proof-of-concept and lead the way for including physical activity intervention in other childhood cancer treatment protocols as well. The results from this study will also enable the researchers to proceed in the planning of the first exercise intervention to be included upfront in an international childhood cancer treatment protocol, the upcoming Pan-European treatment protocol for standard-risk medulloblastoma in children (SIOP-MB6).
Inclusion Criteria: Completed therapy for medulloblastoma, including craniospinal radiation therapy, within 36 months before study entry.
-
Exclusion Criteria: Inability to walk without support. Progressive disease.
-
Video-supervised exercise, offered three times per week for 12 weeks, followed by behavioral support towards incorporating physical activity into daily life for an additional 12 weeks.
Behavioral: Exercise
Moderate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance.
Feasibility of the remote assessment and a digitally delivered exercise intervention
The researchers will test the feasibility of delivering the exercise intervention via video, defined as: 1. Adherence to the intervention by number of completed intervention sessions Acceptable level: ≥70% adherence at 6 months. 2. Data collection - feasibility of outcome measures Criteria: ≥ 90% of video-based measurements can be conducted according to protocol. ≥ 80% of PROM assessments can be completed as planned. 3. Safety Documentation of adverse events (all occurring and documented adverse events associated with the intervention will be recorded in accordance with the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.). 4. Acceptance and perceived usefulness Criterion: Qualitative analysis of interviews shows that the intervention is perceived as meaningful, feasible, and not too burdensome. 5. Technical aspects Criterion: ≥ 90% of participants can complete video sessions without major technical problems, beginning after the first three sessions.
Time frame: From enrollment to the end of exercise at 12 weeks and then for prolonged support for another 12 weeks.
Handgrip strength
Measured with a hand dynamometer
Time frame: Change from baseline, until 3 and 12 months.
Physical activity
Activity counts per day, registered with accelerometry (Fibion Sens)
Time frame: Change from baseline, until 1.5, 3, 6, and 12 months.
Patient-reported quality of life
Measured with Patient-Reported Outcomes Measurement Information System (PROMIS)-25.
Time frame: Change from baseline, until 3 and 12 months.
Motor function
Assessed with the brief ataxia rating scale (BARS), higher numbers indicate worse outcomes.
Time frame: Change from baseline, until 3 and 12 months.
Cardiorespiratory fitness
Assessed with the 3-min step in place test
Time frame: Change from baseline, until 3 and 12 months.
Epigenetic age acceleration
Epigenetic age will be determined from DNA methylation analyses of DNA extracted from saliva samples.
Time frame: Change from baseline, until 3 and 12 months.
Feasibility of the outcome measures
The researchers will develop the outcome assessments battery by removing outcome assessments that are not feasible through video.
Time frame: 12 weeks
Cognitive function
Patient-Reported Outcomes Measurement Information System (PROMIS) cognitive function 7a.
Time frame: Change from baseline to 12 weeks and 12 months.
Lower limb strength
We will assess lower limb strength with the five repetition sit-to-stand test, assessed with the number of seconds to perform the test. The same chair will be used across all time points.
Time frame: Change from baseline until 3 and 12 months.
Plan to share: No — This is a small feasibility study and will not generate data that will be meaningful to share.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.